StandoutStocks.com: "Stocks that Standout" picks for today are: BSGC, BVSN, BVTI, BYBUF, CAGC

Oct 24, 2008 (M2 PRESSWIRE via COMTEX) -- CAGC | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" picks for today are: BigString Corporation (OTCBB: BSGC), BroadVision, Inc. (OTCBB: BVSN), Biovest International, Inc. (OTCBB: BVTI), Buffalo Gold Ltd. (TSX VENTURE: BUF/OTCBB: BYBUF/FRANKFURT: B4K), China Agritech, Inc. (OTCBB: CAGC)....and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Oct 22, 2008 -- BigString Corporation (OTCBB: BSGC), a developer of messaging technology, today (22 October) announced the release of a new text messaging application for Blackberry phones that permits both personal and business users to send self-destructing Short Message Service (SMS) text messages and pictures.

The new application is called SMS Eraser. BigString said that the self-destruction timing of messages is determined by the sender. A message can be set to self-destruct in as little as fifteen seconds or after a set number of views. The message will disappear in real time simultaneously from both the sending and receiving IM screens. Once the message self-destructs it cannot be recovered.

BigString's BlackBerry SMS Eraser is priced at USD29.95 and can be downloaded from BigString's website.

Oct 22, 2008 -- BroadVision, Inc. (OTCBB: BVSN), a global provider of strategic e-business solutions, today reported financial results for its third quarter ended September 30, 2008. Revenues for the third quarter were $8.2 million, compared with revenues of $8.0 million for the second quarter ended June 30, 2008 and $12.8 million for the comparable quarter of 2007.

License revenue for the third quarter of 2008 was $2.1 million, compared with $2.4 million for the prior quarter and $5.3 million for the comparable quarter of 2007. The majority of the third quarter license revenue was generated from the BroadVision(R) core Business Agility Suite(TM), Commerce Agility Suite(TM), eMerchandising(TM) and QuickSilver solutions, from customers including the State of Minnesota, Epson, Raiffeisen Bank, Honeywell and other brand-name, global customers.

In the third quarter of 2008, BroadVision posted net income on a U.S. Generally Accepted Accounting Principles ("GAAP") basis of $0.3 million, or break even per basic and diluted share, as compared with GAAP net income of $1.4 million, or $0.01 per basic and diluted share, for the second quarter of 2008 and GAAP net income of $5.5 million, or $0.05 per basic and diluted share, for the third quarter of 2007.

Non-GAAP measure net income for the third quarter of 2008 was $0.1 million, or break even per basic and diluted share, compared with non-GAAP measure net income of $1.1 million, or $0.01 per basic and diluted share, for the second quarter of 2008 and non-GAAP measure net income of $6.7 million, or $0.06 per basic and diluted share, for the third quarter of 2007. These non-GAAP measure net income figures exclude restructuring charges, stock compensation expense under SFAS 123(R), and revaluation of warrant liabilities. A reconciliation of these non-GAAP measure figures to GAAP net income figures is included in a table on the attached financial statements. The Company believes these non-GAAP measure net income figures provide useful information because they reflect the Company's financial performance excluding certain charges, credits, gains, and losses that the Company believes are not indicative of its ongoing operations.

As of September 30, 2008, the Company had $62.5 million of cash, cash equivalents, and short-term investments, representing a $3.4 million, or 6%, increase over the June 30, 2008 combined balance of $59.1 million, and a 16% increase over the balance as of the end of 2007 of $54.0 million. This increase is due primarily to positive cash flow generated from operations.

"We are making steady progress in the marketplace transitioning to our new generation of products," said Dr. Pehong Chen, President and CEO, BroadVision. "Despite a challenging macroeconomic environment, we are optimistic about future opportunities due to our improved pipeline and visibility; strengthening of revenue backlogs; and a solid balance sheet with strong cash positions."

Conference Call Information

BroadVision management will host a conference call today, Wednesday, October 22, 2008, at 2:00 p.m. PDT. The conference call may be accessed by dialing: 1-866-551-3680, with pincode 6835310#. Callers outside North America should call 1-212-401-6760 to be connected. A web replay will also be available following the call on the Company's website until it releases its fourth quarter 2008 financial results.

About BroadVision

Driving innovation since 1993, BroadVision is a global provider of strategic e-business solutions. Our modular applications and agile toolsets, built on a robust framework for personalization and self-service, power mission-critical web initiatives that deliver unparalleled value to diverse customers worldwide. Hundreds of organizations, serving over 50 million registered users -- including Baker Hughes, BioRad Laboratories, Fiat, Hilti, Iberia, ING Bank, PETCO, Prime Polymer, Verifone, and Xerox -- rely on BroadVision as their platform of choice for e-business.

Oct 22, 2008 -- Biovest International, Inc. (OTCBB: BVTI | Quote | Chart | News | PowerRating) today announced that the U.S. Federal Government has approved the appropriation of $1.6 million in biomedical research funds for Fiscal Year 2009 for the Defense Department's Cancer Immunotherapy and Cell Therapy Initiative, which is intended to support research into new applications for the AutovaxID(TM) instrument, Biovest's fully-automated cell-manufacturing device to cost-effectively and efficiently manufacture difficult-to-produce therapeutic proteins and personalized vaccines, including vaccines targeting cancers.

Biovest's Chairman and CEO, Dr. Steven Arikian, stated, "Congressman James McGovern (D-MA, Third District) and his staff have been wonderful to work with. We have been very impressed with Congressman McGovern's personal commitment in the fight against cancer, and his leadership will ensure that the latest cancer immunotherapy technology gets to military personnel and their dependents expeditiously."

"The U.S. military in recent years has actually been leading the field in cancer immunotherapy research," Dr. Arikian added. "Biovest is proud that its cancer vaccine enabling technology, AutovaxID, will be a major part of the Defense Department's efforts in the national and international fight against cancer."

According to Dr. Arikian, the federal research funds are planned to be used to conduct groundbreaking research with life-saving applications for the U.S. Armed Forces, veterans, and civilians. "Currently, we are utilizing AutovaxID(TM) to manufacture our proprietary personalized anti-cancer vaccine (BiovaxID(R) targeting B-cell blood cancers, such as non-Hodgkin's lymphoma. With this expected critical funding support, we intend to further develop AutovaxID to be capable of growing patient-specific cells that could be used to rebuild damaged tissue or organs. The potential applications following trauma or injury are numerous, such as for the production of autologous skin for burn repair, growth of bone for fracture repair, and/or the production of tissue for plastic reconstruction of severe injuries."

The funds are being provided in the Defense Department's Title VI, Defense Health Program's Research and Development Account in the Defense Appropriations Conference Report. President Bush signed the Continuing Resolution, which included the research funds on September 30, 2008.

About AutovaxID(TM)

By automating the biomanufacturing process, and using single-use, closed-system disposable bioreactors, AutovaxID dramatically cuts the need for supervision, thus also minimizing error-prone manual monitoring and adjustments. Its capabilities actually reduce the need for large, expensive production facilities, including costly isolation suites and clean rooms. Biovest is positioning AutovaxID as a critically important platform technology which allows manufacturers of specialized protein-based drugs to streamline the production process, allowing for the faster and cheaper production of their products, using less manpower, while continuing to adhere with stringent regulatory standards.

About BiovaxID(R)

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

About Biovest International, Inc.

Biovest International, Inc. (OTCBB:BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID(R), which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

Oct 22, 2008 -- Brian McEwen, President and CEO of Buffalo Gold Ltd. (TSX VENTURE:BUF)(OTCBB:BYBUF)(FRANKFURT:B4K) is pleased to announce that the Company has signed a Memorandum of Understanding (M.O.U.) with China Railway Resources Co. LTD. ("CRRC"), a wholly owned subsidiary of China Railway Group Limited ("CREC") (www.crec.cn) to invest directly into the Company as well as finance the Mt Kare project in Papua New Guinea and the grassroots projects in Australia. "CREC" is a public company registered in the People's Republic of China and one of the largest civil construction companies in the world. From January 2008 to June 2008 CREC reported profit attributable to the equity holders of the Company of RMB1.906 billion ($332,000,000 CDN), representing a year-on-year growth of 190%. CREC has created a Resource Development Branch to invest in overseas mineral development projects.

Buffalo Gold's CEO, Brian McEwen commented, "We are very excited to have signed this MOU with CREC. Raising money for early stage projects is extremely difficult in the current market, and as such our Australian properties and even the Mt Kare project have been underexplored for the past year. Buffalo now has a partner with the financial backing to complete exploration and evaluation at Mt Kare and our portfolio of grass roots projects in Australia. This allows us to focus on completing the underground feasibility study at our Furtei operation in Sardinia so that we can increase our revenues from that project."

Under the terms of the M.O.U., CRRC intends to:

- Make an equity investment into Buffalo of $3,000,000 CDN at $0.10 for each unit. Each unit contains one common share and one half share warrant at $0.30 per share for one year from date of closing.

- Make a project investment $7,500,000 CDN into Buffalo's Mt Kare JV with Madison Minerals within 24 months of signing to earn 54% of the project.

- Earn up to 72% in the project by making a cash payment of $5,000,000 CDN to the Mt Kare JV and completing a feasibility study on the project. CRRC will earn 82% with a total project investment of at least $40,000,000 CDN.

- Make a total project investment into Buffalo's Australian portfolio of $2,500,000 CDN to earn 60%. CRRC can earn up to 80% in any of the projects by advancing to the stage of resources as defined in NI 43-101.

The M.O.U. is contingent on CRRC completing due diligence on Buffalo and its assets and receiving all approvals, including approval from the TSX Venture Exchange.

Time is of the essence and the proposed schedule is for CRRC to begin due diligence and site visits and within two weeks of signing and if satisfied with the due diligence to finalize terms and conditions within eight weeks of signing.

Madison-Buffalo joint venture

The interests of Buffalo Gold and Madison Minerals in the Mt. Kare project are currently held via a joint venture agreement dated June 25, 2007 by which Buffalo has a 60% interest and Madison a 40% interest, which is subject to dilution in certain circumstances. Completion of the transactions set out in the M.O.U. would result in the replacement of that joint venture agreement with a new agreement, providing for, among other matters:

- Fixing Madison's interest in the project at 40% of the total retained Madison-Buffalo interest at all stages going forward, not subject to dilution.

- A cash payment from Buffalo to Madison of $352,165 CDN on regulatory acceptance of an agreement in respect of the matters set out in the M.O.U.

- Receipt by Madison of 40% of the $5,000,000 USD cash payment to the JV as set out above.

- Retention by Madison of 3.2% interest in the project at the point of CREC's earning its 82% interest.

- Relief from a requirement that Madison fund a portion of the JV's expenditures on the Mt. Kare project since July 14, 2008 or, in the alternative, face dilution of its interest to an amount less than 40%.

Madison confirms that it is the owner of 3,521,648 shares of Buffalo Gold Ltd.

About CREC

China Railway Group Ltd. ("CREC") is one of the largest civil construction companies in the world and the largest railway, road, bridge and tunnel construction company in Asia. The Company's current ranking in Fortune 500, as published in the US Fortune magazine in 2008, is 341; rank 332 in the ''Top 500 Brands in the World'' list prepared by World Brand Laboratory in 2008; and rank 433 in the ''Global 500'' published in the Financial Times.

About Buffalo Gold Buffalo's vision is to build shareholder value by growing a gold mining company through a combination of exploration and acquisition. The Company became a gold producer in November 2007 with the acquisition of the Furtei mine, and is exploring projects in Sardinia, Papua New Guinea and Australia.

Oct 23, 2008 -- China Agritech, Inc. (OTCBB: CAGC | Quote | Chart | News | PowerRating) ("China Agritech" or "the Company"), a leading national-level liquid organic compound fertilizer manufacturer and distributor in China, today announced the appointment of Mr. Yau-Sing Tang as Chief Financial Officer, effective immediately. With yesterday's appointment of three independent directors of the board, today's announcement will entitle China Agritech to receive $2 million from an escrow account, according to the Escrow Agreement in connection with the 2007 PIPE transaction.

Mr. Tang, 46, was most recently the CFO at Carpenter Tan Holdings Ltd., a retail chain in Mainland China which is applying to be listed on the Hong Kong Stock Exchange. Prior to that, he was the founder and managing director of GC Alliance Limited, CPA firm in Hong Kong. From April 2003 to December 2005, he was executive director and Chief Financial Officer of China Cable and Communication, Inc., which was listed on the OTC Bulletin Board in the U.S.

Mr. Tang received his bachelor of social sciences (Honors) degree from the University of Hong Kong. He is a fellow of the Association of Chartered Certified Accountants in the U.K. and the Hong Kong Institute of Certified Public Accountants. He is also a member of the Institute of Chartered Accountants in England and Wales and the Taxation Institute of Hong Kong.

"Our new board of directors is extremely pleased to welcome Mr. Tang to join our senior management team," said Mr. Yu Chang, Chairman and Chief Executive Officer of the Company. "Mr. Tang brings over 23 years of accounting, corporate finance and financial-reporting experiences. He has worked in telecom, retail and financial services industries and has a strong background in the U.S. GAAP. We look forward to drawing upon Mr. Tang's expertise in financial reporting and his extensive contacts in the financial services industry."

About China Agritech, Inc.

China Agritech, Inc. is engaged in the development, manufacturing and distribution of liquid organic compound fertilizers and related products in China. The Company has developed proprietary formulas that provide a continuous supply of high-quality agricultural products while maintaining soil fertility. The Company sells its products to farmers located in 26 provinces of China.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index